CAPTRUST Financial Advisors’s Impel Pharmaceuticals Inc. Common Stock IMPL Stock Holding History

CAPTRUST Financial Advisors’s Portfolio IMPL Stock Details IMPL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-14,407	Closed	-$6.2K	–	2841
2023 Q3	$6.2K	Hold	14,407	–	–	﹤0.01%	2545
2023 Q2	$18.3K	Hold	14,407	–	–	﹤0.01%	2463
2023 Q1	$20.2K	Buy	+14,407	New	+$34.4K	﹤0.01%	2252
2021 Q4	–	Sell	-140	Closed	-$2K	–	4976
2021 Q3	$2K	Buy	+140	New	+$2.03K	﹤0.01%	4320

Other funds holding IMPL

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

DJSG

D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

CAPTRUST Financial Advisors's IMPL Position: Q4 2023 in Review

CAPTRUST Financial Advisors sold out of Impel Pharmaceuticals Inc. Common Stock (IMPL) in Q4 2023, closing a stake of 14,407 shares — an estimated $6.2K sold.

CAPTRUST Financial Advisors first reported a position in IMPL in Q3 2021 and held it in 4 quarters. The position peaked at $20.2K in Q1 2023. 2 funds tracked by Wall St. Rank hold IMPL as of Q4 2023.

CAPTRUST Financial Advisors reported no remaining Impel Pharmaceuticals Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
CAPTRUST Financial Advisors sold 14,407 Impel Pharmaceuticals Inc. Common Stock shares in Q4 2023, an estimated $6.2K.
CAPTRUST Financial Advisors first reported a position in Impel Pharmaceuticals Inc. Common Stock in Q3 2021 and held it in 4 quarters.
CAPTRUST Financial Advisors's Impel Pharmaceuticals Inc. Common Stock position peaked at $20.2K in Q1 2023.
2 funds tracked by Wall St. Rank held Impel Pharmaceuticals Inc. Common Stock as of Q4 2023.

Based on CAPTRUST Financial Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.